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OBJECTIVE—To analyze the association between pioglitazone use and bladder cancer
through a spontaneous adverse event reporting system for medications.
RESEARCH DESIGN AND METHODS—Case/noncase bladder cancer reports associ-
ated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration
(FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the




weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs
(6 and 4, respectively).
CONCLUSIONS—In agreement with preclinical and clinical studies, AERS analysis is con-
sistent with an association between pioglitazone and bladder cancer. This issue needs constant
epidemiologic surveillance and urgent deﬁnition by more speciﬁc studies.
Diabetes Care 34:1369–1371, 2011
A
link between pioglitazone and
bladder cancer ﬁrst appeared in
preclinical studies and was ﬁrst re-
ported on the U.S. pioglitazone label in
1999, but experimental studies recently
suggested that it might be a rat-speciﬁc
phenomenon (1). In the large PROactive
(PROspective pioglitAzone Clinical Trial
In macroVascular Events) study, 14 blad-
der cancers occurred in the pioglitazone
arm (0.5%) versus 6 in the placebo arm
(0.2%) (2,3), and in September 2010, the
U.S. Food and Drug Administration
(FDA) announced an ongoing investiga-
tion on the possible risk in humans (4).
Accordingly, the drug manufacturer is
conducting a 10-year observational study
to address the long-term risk of bladder
cancer associated with pioglitazone (4).
Veryrecently,theEuropeanMedicines
Agency (EMA) suspended the marketing
authorization of rosiglitazone (5), and the
FDAlargelyrestricteditsusebecauseofan
increased cardiovascular risk (6). These
measures will increase the prescription of
pioglitazone; thus, the deﬁnition of its
beneﬁt/risk proﬁle becomes all the more
pressing.
O u ra i mw a st oc o n t r i b u t et od e ﬁn-
ing the safety proﬁle of pioglitazone, fo-
cusing on cases of bladder cancer recorded
in the FDA Adverse Event Reporting Sys-
tem (AERS) database associated with anti-
diabetic drug treatment.
RESEARCH DESIGN AND
METHODS—The reports recorded in





and consumers from the U.S. and serious
and unlabeled spontaneous reports from
non–U.S. countries. The adverse events
are codiﬁed by Medical Dictionary for
Regulatory Activities (MedDRA)terminol-
ogy. Reports concerning antidiabetic
drugs were selected, provided that age,
sex, and event date were available. Dupli-
cates and multiple records, a well-known
drawback of FDA AERS (7), were ex-
cluded by a semiautomated multistep
process (8).
The association between antidiabetic
drugsandbladdercancerwasanalyzedby
the case/noncase methodology (9). Cases
were the reports retrieved under the
MedDRA high-level term “bladder neo-
plasms” for any given drug; noncases
were all of the other reports related to
the same drug. The association between
the drug and bladder cancer was calcu-
lated by the adverse drug reaction report-
ing odds ratio (ROR) as a measure
of disproportionality. The ratio cases/
noncases for each drug were compared
with the ratio of cases/noncases for all
other antidiabetic drugs. Stratiﬁed analy-
ses weighed the inﬂuence of male sex and
old age. The possible effect of notoriety
bias was tested by a year-by-year analysis.
Epi Info 3.4.3-2007 software (Centers for
Disease Control and Prevention, Atlanta,
GA) was used for statistical analyses.
RESULTS—From2004to2009,86,987
reports involving antidiabetic drugs
were recorded in FDA AERS, correspond-
ing to 599,085 drug-reaction pairs (ob-
tained by splitting comedications and
multiple reactions reported for each
case), with 37,841 reports concerning
pioglitazone. Overall, 93 reports of blad-
der cancer were retrieved, correspond-
ing to 138 drug-reaction pairs, with 31
concerning pioglitazone; 29 insulin; 25
metformin; 13 glimepiride; 8 exenatide; 6
gliclazide; 5 glipizide; 4 sitagliptin, acar-
bose and rosiglitazone; 3 glibenclamide; 2
nateglinide and repaglinide; and 1 phen-
formin and voglibose.
The ROR of bladder cancer was sig-
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Among the 31 cases of bladder cancer re-
ported in pioglitazone users (mean age,
70 years; range 53–84), 23 occurred in
men (3.86 [2.37–6.26]; Supplementary
Table A1) and 8 were in women (5.19
[2.15–12.11]). When stratiﬁed by age
(cutoff, 65), ROR for pioglitazone was
only signiﬁcant in older patients (5.10
[3.14–8.23]). Four cases of bladder can-
cer were reported in 2004, three in 2005,
nine in 2006, ﬁve in 2007, six in 2008,
and four in 2009 (ROR not statisti-
cally signiﬁcant in 2005 and 2009;
Supplementary Table A2).
Ten cases occurred during clinical
studies. The length of drug use, which
was recorded in15cases,was ,6 months
in 6 patients, 6–24 months in 5, and .24
months in 4. Antiplatelet agents (e.g., as-
pirin and clopidogrel), antihypertensive
drugs(e.g.,ACEinhibitorsanddiuretics),
lipid-lowering agents (e.g., statins), other
antidiabetic drugs (e.g., glimepiride, met-
formin,andacarbose),andglucocorticoid
(ﬂuticasone and mometasone) were the
cotreatments most frequently recorded
(24 patients). One patient was being treated
with cytotoxic therapy (inﬂiximab and
methotrexate for psoriatic arthropathy),
and one was treated with interferon-
b-1a for multiple sclerosis.
CONCLUSIONS—Bladder cancer is
the fourth most common cancer and the
ninth leading cause of cancer death
among U.S. men (10).Cigarette smoking,
urinary tract infections, occupational
exposure to aromatic amines and poly-
cyclic aromatic hydrocarbons, and drugs
(e.g., cyclophosphamide) are risk factors
for the disease, as might be the systematic
use of glucocorticoids (11).
Wefoundadeﬁnitesignalforbladder
cancer associated with pioglitazone use.
The demographic characteristics of the
selected cases were consistent with blad-
der cancer epidemiology (male sex, old
age) (10). A weaker signal was also asso-
ciated with gliclazide, and a much weaker
signal was associated with acarbose. Of
note, the occurrence of fewer than ﬁve
events,althoughresultinginastatistically
signiﬁcant ROR, may be considered clin-
ically meaningless because it is too sus-
ceptible to reporting biases (12).
Although notoriety bias may have
contributed to part of the association
between pioglitazone use and bladder
cancer(13),wealsoobservedasigniﬁcant
relationship in 2004, which preceded
publication of the PROactive study (2)
and label revision. Therefore, we do not
believe that our ﬁndings can be explained
by notoriety bias alone. A greater use of
pioglitazone could also have inﬂuenced
this result (14).
Preliminary data found an increasing
risk of bladder cancer with pioglitazone
exposure, with statistical signiﬁcance af-
ter24 months(4).Thisissue could notbe
conﬁrmed by our analysis, with only four
cases of bladder cancer occurring in pa-
tients exposed to pioglitazone for more
than 2 years and several missing data. In
general, the association with bladder
cancer does not seem to derive from con-
comitant drug use or comorbidity, with
only two patients receiving treatments
potentially favoring carcinogenesis and
ﬁve patients receiving glucocorticoids.
The ROR analysis has several limi-
tations: generic under-reporting, over-
reporting generated by notoriety bias,
dependence on the drug-marketing pe-
riod (Weber effect), missing or misspelled
data (7,13,15),and lack of information on
patients’ habits (smoking) or occupa-
tional risks. Despite limitations, the
higher-than-expected reporting of blad-
der cancer for pioglitazone users com-
p a r e dw i t hu s e r so fo t h e ra n t i d i a b e t i c
drugs should stimulate speciﬁc case–
control studies aimed at verifying the
magnitude of the hazard; until the ﬁnal
dataoftheFDAinvestigationareavailable,
physicians should pay careful attention
to this possible risk.
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